PDCD1 and gastric cancer: Due to the limited follow-up period of 19.7 months, the median OS of all the patients was not reached, but the mean OS was 18.5 months (95% CI 16.5-20.6) at the cut-off date March 2022; most R0 patients were alive, and long-term survival benefit has already been confirmed in this population (8–10, 12), so obviously intra-arterial chemotherapy with sequential anti-PD-1 in conversion therapy has improved the survival time of patients with unresectable gastric cancer, which was around one year as reported for palliative chemotherapies (4–6).